Status:

RECRUITING

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Lead Sponsor:

Children's Hospital Medical Center, Cincinnati

Conditions:

Hematologic Malignancy

Leukemia

Eligibility:

All Genders

Up to 38 years

Brief Summary

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tabl...

Detailed Description

Peripheral blood will be drawn at multiple time points to evaluate venetoclax pharmacokinetics in patients who are receiving venetoclax solution made from crushed tablets as part of their oncology tre...

Eligibility Criteria

Inclusion

  • Age: Patients must be \<39 years of age at time of study enrollment
  • Diagnosis: Patients may have a diagnosis of any hematologic malignancy
  • Central access: Patients must have an existing venous or arterial access line for PK blood draws
  • Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment
  • Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.
  • Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.

Exclusion

  • Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.
  • Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.

Key Trial Info

Start Date :

November 15 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06131801

Start Date

November 15 2023

End Date

December 1 2027

Last Update

January 9 2026

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

2

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

3

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

4

Texas Children's Hospital

Houston, Texas, United States, 77030

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | DecenTrialz